Hims Hers Health is trading 5.8% up at $31.39 after rebounding from losses tied to the Federal Trade Commission lawsuit.
- The FTC alleged privacy violations, deceptive billing, and difficult subscription cancellations.
- Hims & Hers denied wrongdoing and said it would vigorously defend itself.
- The recovery extends the rebound from the July 29 low, though the lawsuit remains the key overhang.